A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies.

Kristina Callis DuffinAndrew G BushmakinJoseph C CappelleriLotus MallbrisCarla M Mamolo

Published in: BMC dermatology (2019)

Consistent with previous findings from a phase II study, these results indicate that this PGA is a valid, reliable instrument for evaluating disease severity in clinical studies of psoriasis.

Keyphrases

phase ii study
phase iii
open label
placebo controlled
phase ii
clinical trial
emergency department
primary care
rheumatoid arthritis
study protocol
double blind
locally advanced
atopic dermatitis
case control
ulcerative colitis
rectal cancer
clinical evaluation